Corvus Pharmaceuticals (CRVS) Non-Current Assets (2015 - 2026)

Corvus Pharmaceuticals' Non-Current Assets history runs 12 years deep, the most recent figure standing at $798000.0 for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 34.0% year-over-year to $798000.0 in Q1 2026; TTM through Mar 2026 was $798000.0, a 34.0% decrease from a year earlier, with the FY2025 full-year figure at $904000.0, down 31.31% from the prior year.
• Non-Current Assets retreated to $798000.0 in Q1 2026 per CRVS's latest filing, from $904000.0 in the prior quarter.
• Across five years, Non-Current Assets topped out at $36.9 million in Q1 2022 and bottomed at $798000.0 in Q1 2026.
• The 5-year median for Non-Current Assets is $1.3 million (2023), against an average of $8.1 million.
• Across the five-year window, Non-Current Assets slumped 95.74% in 2023 and grew 0.98% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $1.7 million in 2022, then fell by 13.62% to $1.4 million in 2023, then slipped by 7.78% to $1.3 million in 2024, then sank by 31.31% to $904000.0 in 2025, then slipped by 11.73% to $798000.0 in 2026.
• Per Business Quant, the three latest CRVS Non-Current Assets figures stand at $798000.0 (Q1 2026), $904000.0 (Q4 2025), and $1.0 million (Q3 2025).